KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accounts Payables (2020 - 2026)

AbCellera Biologics filings provide 7 years of Accounts Payables readings, the most recent being $39.6 million for Q1 2026.

  • Quarterly Accounts Payables fell 17.33% to $39.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $39.6 million through Mar 2026, down 17.33% year-over-year, with the annual reading at $50.8 million for FY2025, 7.68% down from the prior year.
  • Accounts Payables hit $39.6 million in Q1 2026 for AbCellera Biologics, down from $50.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $55.0 million in Q4 2024 and bottomed at $24.4 million in Q2 2022.
  • Average Accounts Payables over 5 years is $43.2 million, with a median of $47.8 million recorded in 2025.
  • The largest annual shift saw Accounts Payables skyrocketed 114.82% in 2023 before it dropped 17.33% in 2026.
  • AbCellera Biologics' Accounts Payables stood at $52.5 million in 2022, then dropped by 5.56% to $49.6 million in 2023, then rose by 10.94% to $55.0 million in 2024, then dropped by 7.68% to $50.8 million in 2025, then fell by 22.11% to $39.6 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Accounts Payables are $39.6 million (Q1 2026), $50.8 million (Q4 2025), and $53.1 million (Q3 2025).